Travere Therapeutics (NASDAQ:TVTX) CEO Eric Dube Sells 100,087 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CEO Eric Dube sold 100,087 shares of the business’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $32.28, for a total value of $3,230,808.36. Following the completion of the transaction, the chief executive officer directly owned 432,886 shares in the company, valued at approximately $13,973,560.08. This represents a 18.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Travere Therapeutics Stock Performance

Shares of NASDAQ:TVTX opened at $32.84 on Wednesday. The business has a fifty day moving average of $34.11 and a 200-day moving average of $27.76. The company has a debt-to-equity ratio of 4.23, a quick ratio of 2.71 and a current ratio of 2.75. Travere Therapeutics, Inc. has a twelve month low of $12.91 and a twelve month high of $42.13. The firm has a market cap of $2.94 billion, a PE ratio of -30.98, a price-to-earnings-growth ratio of 1.01 and a beta of 0.83.

Travere Therapeutics News Roundup

Here are the key news stories impacting Travere Therapeutics this week:

• Negative Sentiment: Multiple senior insiders sold large blocks of shares on Feb 3, including CEO Eric M. Dube (100,087 shares, ~18.8% reduction in his position) and several executives (CFO, CAO and other officers) reducing holdings by ~5–10% each — a broad, same-day executive sell-off that can signal rotation or prompt investor concern about near-term insider confidence. CEO Form 4
• Negative Sentiment: A recent article questions Travere’s disclosure and risk narrative, flagging potential credibility concerns that could amplify selling or increase short-term volatility if investors seek more clarity from management. Is Travere Therapeutics (TVTX) Facing a Credibility Test in Its Disclosure and Risk Narrative?

Hedge Funds Weigh In On Travere Therapeutics

Several institutional investors have recently modified their holdings of TVTX. Stephens Investment Management Group LLC bought a new position in Travere Therapeutics during the 3rd quarter worth approximately $38,232,000. Wellington Management Group LLP raised its holdings in Travere Therapeutics by 3,331.9% in the third quarter. Wellington Management Group LLP now owns 1,201,469 shares of the company’s stock worth $28,715,000 after purchasing an additional 1,166,460 shares during the period. Frazier Life Sciences Management L.P. bought a new position in shares of Travere Therapeutics during the second quarter worth $14,831,000. Perceptive Advisors LLC acquired a new position in shares of Travere Therapeutics in the 2nd quarter valued at $12,347,000. Finally, Marshall Wace LLP acquired a new position in shares of Travere Therapeutics in the 2nd quarter valued at $10,992,000.

Analysts Set New Price Targets

A number of brokerages recently weighed in on TVTX. Guggenheim reissued a “buy” rating and issued a $49.00 price target on shares of Travere Therapeutics in a report on Wednesday, January 14th. TD Cowen reissued a “buy” rating on shares of Travere Therapeutics in a research note on Friday, October 31st. Piper Sandler boosted their target price on Travere Therapeutics from $26.00 to $35.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. Wall Street Zen raised Travere Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 13th. Finally, Zacks Research lowered Travere Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 12th. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Travere Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $38.86.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.